Corbus Pharmaceuticals Holdings Inc
F:337
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corbus Pharmaceuticals Holdings Inc
F:337
|
US |
|
A
|
Adf Group Inc
OTC:ADFJF
|
CA |
|
K
|
Kiora Pharmaceuticals Inc
F:7EY0
|
US |
|
L
|
Lazard Ltd
LSE:0UB6
|
BM |
|
Corbus Pharmaceuticals Holdings Inc
LSE:0SZI
|
US |
|
Fobi AI Inc
OTC:FOBIF
|
CA |
|
R
|
Resolute Mining Ltd
DUS:RSM
|
AU |
|
T
|
Tabcorp Holdings Ltd
OTC:TABCF
|
AU |
Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals is a biotechnology company that tries to turn lab-made drug candidates into real medicines for serious diseases, especially cancer. It does not sell a broad portfolio of approved drugs; instead, it spends most of its effort on preclinical work and clinical trials to test whether its compounds are safe and effective enough to become treatments. Because it is still a development-stage drug maker, Corbus usually does not rely on prescription drug sales for revenue. Its money typically comes from financing activities such as issuing stock, and it may also use research partnerships, licensing deals, or similar arrangements to support development. If one of its candidates reaches approval, the business can later earn money from product sales or royalties. What makes Corbus different is that it sits at the risky, early part of the pharmaceutical value chain. It is more like a research engine than a drug factory: it identifies promising biological targets, advances candidates through testing, and often needs bigger drug companies or healthcare partners to carry a medicine through the expensive final stages and into the market.
Corbus Pharmaceuticals is a biotechnology company that tries to turn lab-made drug candidates into real medicines for serious diseases, especially cancer. It does not sell a broad portfolio of approved drugs; instead, it spends most of its effort on preclinical work and clinical trials to test whether its compounds are safe and effective enough to become treatments.
Because it is still a development-stage drug maker, Corbus usually does not rely on prescription drug sales for revenue. Its money typically comes from financing activities such as issuing stock, and it may also use research partnerships, licensing deals, or similar arrangements to support development. If one of its candidates reaches approval, the business can later earn money from product sales or royalties.
What makes Corbus different is that it sits at the risky, early part of the pharmaceutical value chain. It is more like a research engine than a drug factory: it identifies promising biological targets, advances candidates through testing, and often needs bigger drug companies or healthcare partners to carry a medicine through the expensive final stages and into the market.
Cash Position: Corbus reported a record cash position of approximately $127 million, expected to fund operations into early 2024.
Dermatomyositis Progress: The Phase 3 DETERMINE study for lenabasum in dermatomyositis is on schedule, with topline results expected in Q2 2021.
Pipeline Development: Internal CB1 inverse agonist and CB2 agonist programs are advancing, with Phase 1 trials targeted for 2022.
Open-Label Extension: Around 90% of eligible subjects have enrolled in the open-label extension for the dermatomyositis study, with an 8% discontinuation rate.
SSC Program Decisions: Next steps in systemic sclerosis depend on data from ongoing studies and potential FDA openness to post-hoc analysis, inspired by recent Actemra approval.
